Abghari-Gerst M, Armstrong WR, Nguyen K, Calais J, Czernin J, Lin D, Jariwala N, Rodnick M, Hope[HH1] TA, Hearn J, Montgomery JS, Alva A, Reichert ZR, Spratt DE, Johnson TD, Scott PJH, Piert M. A comprehensive assessment of 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients. J Nucl Med. 2021 Jul 29:jnumed.121.262412. Online ahead of print. PMID: 34326126
Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, Behr SC, Zhang L, Barbato F, Ceci F, Farolfi A, Schwarzenböck SM, Unterrainer M, Zacho HD, Nguyen HG, Cooperberg MR, Carroll PR, Reiter RE, Holden S, Herrmann K, Zhu S, Fendler WP, Czernin J, Calais J. Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial. JAMA Oncol. 2021 Sep 16:e213771. Online ahead of print. PMID: 34529005 Health Imaging: PSMA PET in UCLA Prostate Cancer Research DocWire News: 68Ga-PSMA-11 PET Specificity for Pelvic Nodal Metastases
Ferdinandus J, Fendler WP, Farolfi A, Washington S, Mohammad O, Pampaloni MH, Scott PJ, Rodnick M, Viglianti BL, Eiber M, Herrmann K, Czernin J, Armstrong WR, Calais J, Hope TA, Piert MA. PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study. J Nucl Med. 2021 Oct 7:jnumed.121.262821. Online ahead of print. PMID: 34620731 + SNMMI Alavi–Mandell Award 2023 + Health Imaging: EUAs and Prostate Cancer Recurrence Risk
Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach MS, Armstrong WR, Suvannarerg V, Tubtawee T, Grogan T, Elashoff D, Eiber M, Raman SS, Czernin J, Reiter R, Calais J. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2021 Oct 14:jnumed.121.262398. Online ahead of print. PMID: 34649942 + Featured article of the month + Urology Times: PSMA and MRI for Early Prostate Cancer Detection
Crompton J, Armstrong WR, Eckardt MA, Seyedroudbari A, Tap WD, Dry SM, Abt ER, Calais J, Herrmann K, Czernin J, Eilber FC, Benz MR. 18F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma. J Nucl Med. 2021 Sep 30:jnumed.121.262502. Online ahead of print. PMID: 34593596
Mona CE, Benz MR, Hikmat F, Grogan TR, Lückerath K, Razmaria A, Riahi R, Slavik R, Girgis MD, Carlucci G, Kelly KA, French SW, Czernin J, Dawson DW, Calais J. Correlation of 68Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study. J Nucl Med. 2021 Nov 5:jnumed.121.262426. doi: 10.2967/jnumed.121.262426. PMID: 34740953 AuntMinnie: PET imaging lays foundation for new cancer therapies
Martin Ma T, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysł-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Andrew Loblaw D, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU.Refining the Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer: the Phoenix Definition and Beyond. Radiother Oncol. 2021 Nov 10:S0167-8140(21)08797-1. doi: 10.1016/j.radonc.2021.11.005. PMID: 34774650
Morath V, Heider M, Mittelhäuser M, Rolbieski H, Stroh J, Calais J, Eiber M, Bassermann F, Weber WA. Initial evaluation of [18F]-FACBC for PET imaging of multiple myeloma. EJNMMI Res. 2022 Jan 31;12(1):4. doi: 10.1186/s13550-022-00876-0. PMID: 35099620
Gafita A, Rauscher I, Weber M, Hadaschik B, Wang H, Armstrong WR, Tauber R, Grogan TR, Czernin J, Rettig MB, Herrmann K, Calais J, Weber WA, Benz M, Fendler WP, Eiber M. Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med. 2022 Nov;63(11):1651-1658. PMID: 35422442 + SNMMI Alavi–Mandell Award 2023 +
Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, Herrmann K, Weber WA, Calais J, Eiber M, Weber M, Benz MR. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4271-4281. doi: 10.1007/s00259-022-05882-x. PMID: 35767071
Meyer C, Prasad V, Stuparu A, Kletting P, Glatting G, Miksch J, Solbach C, Lueckerath K, Nyiranshuti L, Zhu S, Czernin J, Beer AJ, Slavik R, Calais J, Dahlbom M. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. EJNMMI Res. 2022 Oct 1;12(1):65. doi: 10.1186/s13550-022-00935-6. PMID: 36182983
Gudenkauf LM, Chavez M, Maconi ML, Geiss C, Seyedroudbari A, Thin P, Hoogland AI, Nguyen K, Murthy V, Armstrong WR, Komrokji K, Oswald LB, Jim HSL, El-Haddad G, Fendler WP, Herrmann K, Cella D, Czernin J, Hofman MS, Dicker AP, Calais J, Tagawa ST, Gonzalez BD. Developing a novel patient reported outcomes measure for prostate cancer patients receiving radionuclide therapy. J Nucl Med. 2023 Jan 12:jnumed.122.264946. Online ahead of print. PMID: 36635088 Moffit: Moffitt Researchers Develop Tool to Measure Patient Health and Well-Being after Radionuclide Therapy
Sonni I, Dal Pra A, O'Connell DP, Ells Z, Benz M, Nguyen K, Yoon SM, Deng J, Smith C, Grogan T, Nickols NG, Cao M, Kishan AU, Calais J. PSMA PET/CT-based Atlas for Prostatic Bed Recurrence after Radical Prostatectomy: Clinical Implications for Salvage Radiation Therapy Contouring Guidelines. J Nucl Med. 2023 Feb 9:jnumed.122.265025. doi: 10.2967/jnumed.122.265025. PMID: 36759200 PSMA PET Improves Decision Making for Prostate Cancer Treatment
Smith CP, Xiang M, Armstrong WR, Nickols NG, Steinberg ML, Reiter RE, Rettig M, Weiner AB, Shen J, Valle L, Czernin J, Calais J, Kishan AU. Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00181-5. PMID: 36863416
Ma T, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg M, Dahlbom M, Reiter R, Rettig M, Cao M, Calais J, Kishan AU. LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988. PMID: 36797449
Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, Ma TM, Davicioni E, Xiang M, Kishan AU. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2023 Mar 2:S2588-9311(23)00041-X. doi: 10.1016/j.euo.2023.02.009. PMID: 36870853
Kuo PH, Yoo DC, Avery R, Seltzer M, Calais J, Nagarajah J, Weber WA, Fendler WP, Hofman MS, Krause BJ, Brackman M, Kpamegan E, Ghebremariam S, Benson T, Catafau AM, Kendi AT. A VISION Substudy of Reader Agreement on 68Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177Lu-PSMA-617 Radioligand Therapy. J Nucl Med. 2023 Aug;64(8):1259-1265. PMID: 37230533
Fizazi K, Herrmann K, Krause BJ, Rahbar K, Chi KN, Morris MJ, Sartor O, Tagawa ST, Kendi AT, Vogelzang N, Calais J, Nagarajah J, Wei XX, Koshkin VS, Beauregard JM, Chang B, Ghouse R, DeSilvio M, Messmann RA, de Bono J. Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023 Jun;24(6):597-610. doi: 10.1016/S1470-2045(23)00158-4. PMID: 37269841
Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, Lopci E, Unterrainer LM, Kramer KKM, Schmidt-Hegemann NS, Casuscelli J, Stief CG, Ricke J, Bartenstein P, Kunz WG, Mehrens D. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023 Jul 10. doi: 10.1007/s00259-023-06332-y. PMID: 37428216
Crane JN, Graham DS, Mona CE, Nelson SD, Samiei A, Dawson DW, Dry SM, Masri MG, Crompton JG, Benz MR, Czernin J, Eilber FC, Graeber TG, Calais J, Federman NC. Fibroblast Activation Protein Expression in Sarcomas. Sarcoma. 2023 Jun 9;2023:2480493. PMID: 37333052.
Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Calais J, Rettig M, Eiber M, Weber M, Benz MR, Farolfi A. Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. Radiology. 2023 Jul;308(1):e222148. doi: 10.1148/radiol.222148. PMID: 37432081 Pluvicto patient response criteria validated
Hope TA, Benz M, Jiang F, Thompson D, Barbato F, Juarez R, Hernandez Pampaloni M, Allen-Auerbach M, Gupta P, Fendler WP, Calais J. Do Bone Scans Overstage Disease Compared with PSMA PET at Initial Staging? An International Multicenter Retrospective Study with Masked Independent Readers. J Nucl Med. 2023 Aug 17:jnumed.123.265916. PMID: 37591547 UCSF: For Some Prostate Cancer Patients, PSMA PET May Be Better for Initial Staging of Disease
Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 Sep 7:jnumed.122.265155. PMID: 37678927
Koerber SA, Röhrich M, Walkenbach L, Liermann J, Choyke PL, Fink C, Schroeter C, Spektor AM, Herfarth K, Walle T, Calais J, Kauczor HU, Jaeger D, Debus J, Haberkorn U, Giesel FL Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers. J Nucl Med. 2023 Sep 7:jnumed.123.266046. PMID: 37678928 AuntMinnie: FAPI-PET/CT may improve treatment of cancer patients
Murthy V, Appiah-Kubi E, Nguyen K, Thin P, Hotta M, Shen J, Drakaki A, Rettig M, Gafita A, Calais J (Co-last author), Sonni I,. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. Eur J Hybrid Imaging. 2023 Oct 2;7(1):18. doi: 10.1186/s41824-023-00178-1. PMID: 37779132.
Meyer C, Stuparu A, Lueckerath K, Calais J, Czernin J, Slavik R, Dahlbom M. Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. J Nucl Med. 2023 Nov;64(11):1772-1778. doi: 10.2967/jnumed.123.265433. PMID: 37797974
Sonni I, Gafita A, Unterrainer LM, Alano RM, Lira S, Shen J, Drakaki A, Grogan T, Rettig MB, Czernin J, Calais J. Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. EJNMMI Res. 2023 Oct 30;13(1):95. doi: 10.1186/s13550-023-01048-4. PMID: 37902861
Maliha PG, Hotta M, Czernin J, Calais J. Characterizing Normal Variant [68Ga]Ga-FAPI-46 Uptake in the Epididymis. J Nucl Med. 2023 Nov 9:jnumed.123.266013. doi: 10.2967/jnumed.123.266013. PMID: 37945382
L Emmett, N Papa, W Counter, J Calais, F Barbato, I Burger, M Eiber, MJ. Roberts, S Agrawal, A Franklin, A Xue, K Rasiah, N John, D Moon, M Frydenberg, J Yaxley, P Stricker, K W, G Coughlin, T Gianduzzo, B Kua, B Ho, A Nguyen, V Liu, J Lee, E Hsiao, T Sutherland, E Perry, WP Fendler, TA. Hope.Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database. J Nucl Med 2023 Nov 30: jnumed.123.266164. doi: 10.2967/jnumed.123.266164. PMID: 38050155
Farolfi A, Armstrong WR, Djaileb L, Gafita A, Hotta M, Allen-Auerbach M, Unterrainer LM, Fendler WP, Rettig M, Eiber M, Hofman MS, Hadaschik B, Herrmann K, Czernin J, Calais J, Benz MR. Differences and Common Ground in 177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers. J Nucl Med. 2024 Jan 18:jnumed.123.266391. doi: 10.2967/jnumed.123.266391. Online ahead of print. PMID: 38238041
Armstrong WR, Kishan AU, Booker KM, Grogan TR, Elashoff D, Lam EC, Clark KJ, Steinberg ML, Fendler WP, Hope TA, Nickols NG, Czernin J, Calais J. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774). Eur Urol. 2024 Jan 29:S0302-2838(24)00013-7. doi: 10.1016/j.eururo.2024.01.012. Online ahead of print. PMID: 38290964 AuntMinnie:PSMA-PET helps plan treatment in men with relapsed prostate cancer
Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, Herrmann K, Hofman MS, Eiber M, Hadaschik BA. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. Eur Urol. 2024 Mar 14:S0302-2838(24)00054-X. doi: 10.1016/j.eururo.2024.01.019. PMID: 38490855
Maliha PG, Hotta M, Farolfi A, Grogan T, Alano R, Limon A, Lam E, Carlucci G, Bahri S, Salavati A, Benz M, Silverman D, Gupta P, Quon A, Allen-Auerbach M, Czernin J, Calais J. FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis. Eur J Nucl Med Mol Imaging. 2024 May 16. doi: 10.1007/s00259-024-06733-7. Online ahead of print. PMID: 38750372
Nikitas J, Rettig M, Shen J, Reiter R, Lee A, Steinberg ML, Valle LF, Sachdeva A, Romero T, Calais J, Czernin J, Nickols NG, Kishan AU. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial. Eur Urol. 2024 Mar 16:S0302-2838(24)00058-7. doi: 10.1016/j.eururo.2024.01.021. Online ahead of print. PMID: 38494380
Nikitas J, Lam E, Booker KA, Fendler WP, Eiber M, Hadaschik B, Herrmann K, Hirmas N, Lanzafame H, Stuschke M, Czernin J, Steinberg ML, Nickols NG, Kishan AU, Calais J. Randomized Trial of Prostate-Specific Membrane Antigen PET/CT Before Definitive Radiotherapy for Unfavorable Intermediate- and High-Risk Prostate Cancer (PSMA-dRT Trial).
Gafita A, Djaileb L, Rauscher I, Fendler WP, Hadaschik B, Rowe SP, Herrmann K, Solnes LB, Calais J, Rettig MB, Weber M, Farolfi A, Benz MR, Eiber M. RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2024 Apr 18:jnumed.123.267234. doi: 10.2967/jnumed.123.267234. PMID: 38637143
Nikitas J, Subramanian K, Gozal NB, Ricaurte-Fajardo A, Li E, Proudfoot JA, Davicioni E, Marciscano AE, Osborne JR, Barbieri CE, Armstrong WR, Smith CP, Valle LF, Steinberg ML, Boutros PC, Nickols NG, Rettig MB, Reiter R, Weiner AB, Calais J, Czernin J, Ross AE, Kim EH, Nagar H, Kishan AU.Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. JCO Precis Oncol. 2024 Jul;8:e2400161. doi: 10.1200/PO.24.00161. PMID: 39013135
Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, Eiber M, Barbato F, Moon D, Counter W, John N, Xue A, Franklin A, Thompson J, Rasiah K, Frydenberg M, Yaxley J, Buteau J, Agrawal S, Ho B, Nguyen A, Liu V, Lee J, Woo H, Hsiao E, Sutherland T, Perry E, Stricker P, Hofman MS, Kasivisvanathan V, Roberts M, Murphy D. Beyond Prostate Imaging Reporting and Data System: Combining Magnetic Resonance Imaging Prostate Imaging Reporting and Data System and Prostate-Specific Membrane Antigen-Positron Emission Tomography/Computed Tomography PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer. J Urol. 2024 Aug;212(2):299-309. doi: 10.1097/JU.0000000000004010. Epub 2024 May 17. PMID: 38758680
Weiner AB, Agrawal R, Wang NK, Sonni I, Li EV, Arbet J, Zhang JJH, Proudfoot JA, Hong BH, Davicioni E, Kane N, Valle LF, Kishan AU, Pra AD, Ghadjar P, Sweeney CJ, Nickols NG, Karnes RJ, Shen J, Rettig MB, Czernin J, Ross AE, Lee Kiang Chua M, Schaeffer EM, Calais J, Boutros PC, Reiter RE. Molecular Hallmarks of Prostate-specific Membrane Antigen in Treatment-naïve Prostate Cancer. Eur Urol. 2024 Sep 17:S0302-2838(24)02597-1. doi: 10.1016/j.eururo.2024.09.005. PMID: 39294048 Urology Times: PSMA levels linked to tumor biology, treatment sensitivity in treatment-naïve prostate cancer
Hotta M, Kim GHJ, Rerkpichaisuth V, Teng PY, Armstrong WR, Carlucci G, Dahlbom M, Abtin F, Lari SM, Fishbein GA, Czernin J, Volkmann ER, Weigt SS, Calais J. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease. J Nucl Med. 2024 Nov 1;65(11):1789-1794. doi: 10.2967/jnumed.124.268351. PMID: 39362770
Nikitas J, Gafita A, Benz MR, Djaïleb L, Farolfi A, Hotta M, Sonni I, Alano R, Rettig M, Shen J, Armstrong W, Grogan T, Liu S, Czernin J, Calais J. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. Sci Rep. 2024 Oct 18;14(1):24411. doi: 10.1038/s41598-024-75589-6. PMID: 39420060 Urology Times: Jeremie Calais, MD, highlights study of PSMA-PET vs bone scan in metastatic prostate cancer
Weiner AB, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D, Ludwig VB, Carlucci G, Grant R, Czernin J, Calais J(co-last author), Reiter RE. Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial. Eur Urol Open Sci. 2024 Oct 15;70:36-42. doi: 10.1016/j.euros.2024.09.004. eCollection 2024 Dec. PMID: 39483519
Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J.Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363 Urology Times: Addition of PSMA PET led to notable stage migration in mHSPC, study shows
Unterrainer LM, Hope TA, Fendler WP, Grogan T, Ndlovu H, Armstrong W, Barbato F, Benz MR, Rettig MB, Kishan AU, Sathekge M, Herrmann K, Czernin J, Calais J. Low- and High-Volume Disease in Metastatic Hormone-Sensitive Prostate Cancer: From CHAARTED to PSMA PET-An International Multicenter Retrospective Study. J Nucl Med. 2025 Jan 3;66(1):54-60. doi: 10.2967/jnumed.124.268441. PMID: 39753363
Ells Z, Ludwig V, Weiner AB, Kimura K, Farolfi A, Chamie K, Shirk J, Donin NM, Reiter R, Czernin J, Calais J(co-last author), Dahlbom M. A free method for patient-specific 3D-VR anatomical modeling for presurgical planning using DICOM images and open-source software. Methods. 2025 Feb 21;236:10-16. doi: 10.1016/j.ymeth.2025.02.006. Online ahead of print. PMID: 39988309
